ivosidenib 可提高胆管癌患者的 OS。
Ivosidenib Boosts OS in Cholangiocarcinoma.
出版信息
Cancer Discov. 2021 Dec 1;11(12):2953-2954. doi: 10.1158/2159-8290.CD-NB2021-0389.
Abstract
Ivosidenib extends overall survival in patients with previously treated, advanced cholangiocarcinoma whose disease harbors IDH1 mutations. Median overall survival was 10.3 months in patients who received the drug, versus 7.5 months in the placebo group. The difference was even larger-5.1 months-when researchers accounted for patient crossover into the treatment group.
摘要
ivosidenib 可延长既往治疗的、存在 IDH1 突变的晚期胆管癌患者的总生存期。接受该药物治疗的患者中位总生存期为 10.3 个月，安慰剂组为 7.5 个月。当研究人员考虑到患者交叉进入治疗组时，差异更大-5.1 个月。
Zotero 插件